Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M

Immunovant, Inc.

IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.
New batoclimab programs: Phase 2b in CIDP (start by end-2022) and Phase 2 in Graves' disease (early 2023).
Pro forma cash $476M after $70M October 2022 equity offering; cash runway into H2 2025.
Q2 net loss $47.9M ($0.41/sh) vs $37.7M ($0.35/sh) YoY; R&D expenses rose to $37.7M.
IMVT-1402 IND submission early 2023, initial data mid-2023; batoclimab MG and TED trials on track.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunovant, Inc. reported its fiscal second quarter and six months ended September 30, 2022 results: net income Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022, EPS $0.76 per common share.

Period: its fiscal second quarter and six months ended September 30, 2022
Net income: Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022
EPS: $0.76 per common share
Result: reported results

Exact text from the filing

Net loss was $47.9 million ($0.41 per common share) for the three months ended September 30, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Period: its fiscal second quarter and six months ended September 30, 2022
Net income: Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022
EPS: $0.76 per common share
Result: reported results

Exact text from the filing

Net loss was $88.3 million ($0.76 per common share) for the six months ended September 30, 2022

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-22-000139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.